Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study

Pfizer (PFE) Surges 8%, Merck (MRK) Down 5% Following Pfizer's COVID-19 Oral Antiviral Treatment Data

November 5, 2021 6:49 AM EDT

Pfizer (NYSE: PFE) Surges 8%, Merck (NYSE: MRK) Down 5% Following Pfizer's COVID-19 Oral Antiviral Treatment Data

... More